An interventional study of Acupressure Therapy and Best Practice in Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 and Clinical Stage II Gastric Cancer AJCC v8, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of Washington · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 1,441st largest by enrollment of the 1,573 interventional ones that give a count, is one of 68 that started in 2024, is one of 246 with no phase, and was the 1,597th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Anova Innovation Limited · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
IMGT Co., Ltd. · Sites in United States, Korea, Republic of
Ages 18–85
AdventHealth · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,850 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 777 · Phase 2 721 · Phase 3 91 · Phase 4 12
First in 1991; this study’s year is marked. 68 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 37 across the 1,573 interventional studies, 137 across the 230 observational. Of the 1,223 that completed or were terminated, 479 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
576 of 1,850 have an industry lead sponsor. The 10 most frequent:
University of Washington is the lead sponsor of 1,435 studies on the registry; 225 are open to participants now.
Of its 158 completed or terminated interventional studies of FDA-regulated products, 137 (87%) have results posted.
University of Washington has 5 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
161 of the studies in Pancreatic Neoplasms with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05720338Phase 3Case Comprehensive Cancer CenterIs Intraperitoneal Drainage Necessary Following Distal Pancreatectomy? | 2026-12-31 |
| NCT03257033Phase 3RenovoRxIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | 2027-06 |
| NCT06861088Phase 3Quercis Pharma AGThe Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | 2027-10-31 |
| NCT04275557H. Lee Moffitt Cancer Center and Research InstituteUsing Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | 2026-11 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
Add all 161 to your calendar (.ics) → With an account.
Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial evaluates the feasibility and acceptability of acupressure to the ear (auricular) to address appetite and weight in patients with stage II-IV gastric, esophageal, or pancreatic cancer. Cancer anorexia, the abnormal loss of appetite, directly leads to cancer-associated weight loss (cachexia) through malnourishment, reduced caloric intake, treatment side-effects, and other modifiable risk factors. Cachexia prolongs length of hospital stay for patients, negatively impacts treatment tolerance and adherence, and reduces overall patient quality of life. Auricular acupressure is a form of micro-acupuncture that exerts its effect by stimulating the central nervous system using adhesive taped pellets applied to specific locations on the external ear. The use of these pellets to deliver auricular acupressure has been shown to improve pain, fatigue, insomnia, nausea and vomiting, depression, and quality of life in both cancer and non-cancer settings. Auricular acupressure is a safe, inexpensive, and non-invasive approach to addressing cancer-related symptoms and treatment side-effects and may be effective at improving appetite and weight loss in stage II-IV gastric, esophageal, and pancreatic cancer patients.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
ARM II: Patients receive usual care on study. Patients also undergo collection of blood samples on study.
After completion of study treatment, patients in Arm II are followed up at 8 weeks after active treatment ends.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo auricular acupressure in addition to their usual care on study. Patients also undergo collection of blood samples on study.
Procedure: Acupressure Therapy · Other: Best Practice · Procedure: Biospecimen Collection · Other: Questionnaire Administration
Patients receive usual care on study. Patients also undergo collection of blood samples on study.
Other: Best Practice · Procedure: Biospecimen Collection · Other: Questionnaire Administration
Undergo auricular acupressure
Also known as: Acupressure, Ischemic Compression
Receive usual care
Also known as: standard of care, standard therapy
Undergo collection of blood samples
Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection
Ancillary studies
Also known as: Quality of Life Assessment
Accrual (Feasibility)
Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period.
Time frame: Up to 2 years, during study accrual
Retention (Feasibility)
Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit.
Time frame: Up to 8 weeks
Intervention Adherence (Feasibility)
Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8.
Time frame: Up to 8 weeks
Intervention Fidelity (Feasibility)
Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis.
Time frame: Up to 8 weeks
Acceptability (Feasibility)
Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews.
Time frame: Up to 16 weeks
Change in Appetite
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.
Time frame: Baseline to week 4
Change in Appetite
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.
Time frame: Baseline to week 8
Change in Body Weight (kg)
Analyses will assess change in each outcome as a change from baseline to week 4.
Time frame: Baseline to week 4
Change in Body Weight (kg)
Analyses will assess change in each outcome as a change from baseline to week 8.
Time frame: Baseline to week 8
| Milestone | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Started | 0 | 3 |
| Completed | 0 | 1 |
| Not completed | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 0 | 1 |
Accrual will be measured by the average rate of participants-per-month enrolled into both groups with the goal of 5 patients/month over a 15-month period.
| Participants | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Accrual (Feasibility) | — | 3 |
Retention will be measured by the number of participants who remain in the trial and provide data at the closeout visit.
| Participants | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Retention (Feasibility) | — | 1 |
Adherence will be measured in the intervention group by the number of applied auricular acupressure treatments, with the total possible being 8.
No measurements were reported for this outcome.
Fidelity will be assessed by study team adherence to symptom query and appropriate ear seed point modifications to the standard protocol and accuracy of seed placement according to photographic analysis.
No measurements were reported for this outcome.
Acceptability will be assessed using a random convenience sample of participants and providers through semi-structured interviews.
No measurements were reported for this outcome.
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 4. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.
| score on a scale | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Change in Appetite | — | 1.5 (-1 to 2) |
As measured by the Functional Assessment for Anorexia/Cachexia Treatment Subscale. Analyses will assess change in each outcome as a change from baseline to week 8. The Functional Assessment for Anorexia/Cachexia Treatment Subscale is a 12-item subscale that measures the symptoms and concerns of patients with anorexia/cachexia. The subscale can be used as a standalone instrument. Patients rate each item from 0 to 4 (0 = Not at all; 1 = A little bit; 2 = Somewhat; 3 = Quite a bit; and 4 = Very Much). The recall period for each question is "during the past 7 days". As each of the 12 items ranges from 0-4, the range of possible scores is 0-48, with 0 being the worst possible score and 48 the best. To obtain the 0-48 score each negatively-worded item response is recoded so that 0 is a bad response and 4 is good response.
| score on a scale | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Change in Appetite | — | -3 |
Analyses will assess change in each outcome as a change from baseline to week 4.
| kg | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Change in Body Weight (kg) | — | -0.27 |
Analyses will assess change in each outcome as a change from baseline to week 8.
| kg | Arm I (Acupressure Therapy) | Arm II (Usual Care) |
|---|---|---|
| Change in Body Weight (kg) | — | -1.72 |
Collected over Adverse events were collected throughout the intervention period (8 weeks).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I (Acupressure Therapy) | — | — | — |
| Arm II (Usual Care) | 1/3 (33.3%) | 0/3 (0%) | 0/3 (0%) |
Three participants were randomized into Arm II (usual care). No participants were randomized into Arm I (acupressure therapy).
| Age, Categorical(Participants) | Arm I (Acupressure Therapy) | Arm II (Usual Care) | Total |
|---|---|---|---|
| <=18 years | — | 0 | 0 |
| Between 18 and 65 years | — | 3 | 3 |
| >=65 years | — | 0 | 0 |
| Age, Continuous(years) | Arm I (Acupressure Therapy) | Arm II (Usual Care) | Total |
|---|---|---|---|
| Mean | — | 54 (45 to 62) | 54 (45 to 62) |
| Sex: Female, Male(Participants) | Arm I (Acupressure Therapy) | Arm II (Usual Care) | Total |
|---|---|---|---|
| Female | — | 1 | 1 |
| Male | — | 2 | 2 |
| Race (NIH/OMB)(Participants) | Arm I (Acupressure Therapy) | Arm II (Usual Care) | Total |
|---|---|---|---|
| American Indian or Alaska Native | — | 0 | 0 |
| Asian | — | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | — | 0 | 0 |
| Black or African American | — | 0 | 0 |
| White | — | 3 | 3 |
| More than one race | — | 0 | 0 |
| Unknown or Not Reported | — | 0 | 0 |
| Region of Enrollment(participants) | Arm I (Acupressure Therapy) | Arm II (Usual Care) | Total |
|---|---|---|---|
| United States | — | 3 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results reported in published articles after de-identification may be made available upon request (text, tables, figures, and appendices).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months and ending 36 months after publication of results or study protocol, as requested.
Access criteria: Researchers and investigators who: 1) provide a methodologically sound proposal to expand on aims in the original, approved proposal; and/or 2) aim to conduct individual, participant-level meta-analyses. Proposals should be directed to blangley@fredhutch.org. To gain access, data requestors will need to sign a data access agreement.
Ran from Jul 2024 to primary completion in Jul 2025, 11 months.
Results were first posted in Nov 2026, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.